Isis is developing alicaforsen, an RNase H-dependent antisense inhibitor of intercellular adhesion molecule-1, for the potential treatment of ulcerative colitis. The therapy is currently undergoing phase II clinical trials.
References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.
Isis is developing alicaforsen, an RNase H-dependent antisense inhibitor of intercellular adhesion molecule-1, for the potential treatment of ulcerative colitis. The therapy is currently undergoing phase II clinical trials.
Current opinion in molecular therapeutics – Pubmed
Published: Sep 13, 2005
Access the full text.
Sign up today, get DeepDyve free for 14 days.